Juventas Therapeutics
PRNewswire-USNewswire, August 20, 2012
Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure. Dr. Amit Patel, the Director of Clinical Regenerative Medicine at University of Utah Medical Center, treated the patient.
Cleveland Heart Inc.
Innovation, July 16, 2012
Cleveland Clinic Spin-Off Company, Cleveland Heart Inc., Receives $30 Million Investment for Development of Artificial Heart
Juventas Therapeutics
PRNewswire, July 16, 2012
Juventas Therapeutics, a clinical-stage regenerative medicine company, announced today that it has closed a $22.2 million Series B financing that was co-led by Triathlon Medical Venture Partners and New Science Ventures
Cleveland Clinic Medical Device Solutions
Crain’s Cleveland Business, January 9, 2012
Surgeons and other doctors who perform miracles get most of the limelight at the Cleveland Clinic, but in the basement of its main campus, a crew of machinist, fabricators, engineers and researchers does impressive work, too –
Philips Healthcare
cleveland.com, December 20, 2011
With Philips Healthcare and Steris Corp. expecting to add 200 local jobs within a year, state and local leaders see more proof that Northeast Ohio’s medical economy can compete on a national – and sometimes global – stage.
Philips Healthcare
cleveland.com, December 19, 2011
Two healthcare heavyweights will bring jobs to Northeast Ohio, building up the region’s medical core with help from state incentives.
Ischemia Care
MedCity News, September 1, 2011
A company that’s hoping to be the first to commercialize a blood test that can diagnose the cause of stroke has closed $800,000 of an anticipated $1.1 million series B round of investment.
Global Cardiovascular Innovation Center